Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RPTP's 30-Y Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RPTP Guru Trades in Q1 2016

Jim Simons 572,946 sh (+7.52%)
Steven Cohen Sold Out
Paul Tudor Jones 119,056 sh (-35.74%)
» More
Q2 2016

RPTP Guru Trades in Q2 2016

Jim Simons Sold Out
Paul Tudor Jones 108,286 sh (-9.05%)
» More
Q3 2016

RPTP Guru Trades in Q3 2016

Mario Gabelli 99,450 sh (New)
Jim Simons 126,480 sh (New)
Joel Greenblatt 16,756 sh (New)
Paul Tudor Jones 142,555 sh (+31.65%)
» More
Q4 2016

RPTP Guru Trades in Q4 2016

Mario Gabelli Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RPTP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2016-12-31 Sold Out 0.01%$8.98 - $9 $ 9.000%0
Joel Greenblatt 2016-12-31 Sold Out $8.98 - $9 $ 9.000%0
Mario Gabelli 2016-09-30 New Buy0.01%$5.6 - $9 $ 9.0027%99,450
Joel Greenblatt 2016-09-30 New Buy$5.6 - $9 $ 9.0027%16,756
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Traded in other countries:XYXR.Germany,
Headquarter Location:USA
Raptor Pharmaceutical Corp is a biopharmaceutical company. It is engaged in developing and commercializing transformative treatments for people affected by rare and debilitating diseases.

Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in additional expense.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $109.97
EPS (TTM) $ -1.03
Short Percentage of Float4.72%
52-Week Range $2.94 - 9.05
Shares Outstanding (Mil)85.31

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 129 160 189 225
EPS ($) -0.90 -0.32 -0.17 0.16
EPS without NRI ($) -0.90 -0.32 -0.17 0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for RPTP


Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat